{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31","upperLimit":"47","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"}],"units":"Participants"}],"description":"Prevention of complete removal of at least one kidney in 50% of patients with bilateral Wilms tumor (BWT).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.\n\nDactinomycin: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTherapeutic Conventional Surgery: Undergo surgical resection\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Arm 1 (Bilateral Wilms Tumors)"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable Bilateral Wilms Tumor patients who completed pre-nephrectomy chemotherapy (VAD). 49 patients who did not complete VAD were excluded.","reportingStatus":"POSTED","timeFrame":"12 weeks from study entry","title":"Kidney Preservation After Preoperative Chemotherapy","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}